Comparative Efficacy of Montelukast-Levocetirizine Combination Therapy versus Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis
International Archives of Allergy and Immunology · 2025
DOI: 10.1159/000547410 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Ji-Sun Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Repu…. Hauptthemen laut MEDLINE: Cetirizine, Cyclopropanes, Sulfides, Rhinitis, Allergic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Combination therapy with antihistamines and leukotriene receptor antagonists (LTRAs) is frequently used in allergic rhinitis (AR), particularly in patients with persistent or inadequately controlled symptoms. However, supporting evidence has been inconsistent. This meta-analysis assessed the efficacy of montelukast combined with levocetirizine in patients with AR by directly comparing the combination therapy with each monotherapy and evaluating individual symptom domains.
Methods
A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, with database searches performed through March 2025. Outcomes included daytime and nighttime total symptom scores, individual nasal symptoms, rhinoconjunctivitis-related quality of life (RQLQ), and treatment-emergent adverse events (TEAEs). Pooled effects were calculated using standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs).
Results
Seven RCTs (n = 887) were included. Combination therapy resulted in greater improvement in daytime symptoms (SMD [95% CI]: −0.42 [–0.64 to −0.20]), rhinorrhea (SMD [95% CI]: −0.69 [–1.09 to −0.30]), and nasal congestion (SMD [95% CI]: −0.64 [–1.05 to −0.24]) compared to monotherapy. RQLQ scores improved modestly overall (SMD [95% CI]: −0.37 [–0.72 to −0.01]), but subgroup analyses showed no significant difference compared to individual agents. TEAE rates were similar across groups (OR [95% CI]: 1.05 [0.57 to 1.94]).
Conclusion
Montelukast-levocetirizine combination therapy provided superior symptom control without increased adverse events, supporting its use as a potential treatment option in selected patients with AR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, yellobird@catholic.ac.kr.
Zitieren
APA
Kim, J. S., Stybayeva, G., & Hwang, S. H. (2025). Comparative Efficacy of Montelukast-Levocetirizine Combination Therapy versus Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology. https://doi.org/10.1159/000547410
Vancouver
Kim JS, Stybayeva G, Hwang SH. Comparative Efficacy of Montelukast-Levocetirizine Combination Therapy versus Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology. 2025. doi:10.1159/000547410
BibTeX
@article{Kim2025,
author = {Kim, Ji-Sun and Stybayeva, Gulnaz and Hwang, Se Hwan},
title = {Comparative Efficacy of Montelukast-Levocetirizine Combination Therapy versus Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis},
journal = {International Archives of Allergy and Immunology},
year = {2025},
doi = {10.1159/000547410}
}
EUVIMED